

# **Genome Project and Genomic Approaches to Disease**

**In considering the Genome Project the following should be appreciated:**

- \* Important to understand enabling developments that historically had to be put in place.**
- \* To grasp that the Human Genome Project is the product of a number of genome projects that interact.**

# **Key stages in the evolution of the Human Genome Project:**



## **1956 Chromosomology.**

**The correct number of human chromosomes established.**

**The karyotype = the clinical geneticist's organ of investigation.**



## **1966 Somatic Cell Genetics.**

**Mapping of genes for inborn errors of metabolism and cancer to individual chromosomes and regions.**



## **1976 Mammalian Molecular Genetics.**

**Enabling cloning technology.**



## **1986 Transgenic/Homologous**

## **Recombination Technology.**

**The ability to study gene function.**



## **1996 Large Scale Genome**

**Analysis - Genomics. Building genetic maps, physical maps and DNA sequencing.**

# What is meant by the Genome Project?


## Aims

- \* Build genetic map of genome.**
- \* Sequence genome and identify all genes.**
- \* Understand function and biology of genes**
- \* Map disease gene loci and identify disease genes and understand disease gene biology and related pathophysiology.**

# Strategy Driving the Genome Project - I



**Genetic map**  
built with poly-  
morphic markers:  
RFLP, VNTR, MS,  
SNP



**Physical map**  
of overlapping  
DNA clones  
isolated from  
genomic libraries  
made in large insert  
cloning vectors.  
PACs, **BACs**, YACs




**Genome sequence based on ordered  
physical clone map**



**Computational  
gene identification**

# Strategy Driving the Genome Project - II



# Why study other genomes?

**\* Yeast**

**\* C. elegans**

**\*Drosophila**

**\*Fugu (Puffer fish)**

**\*Mouse**

**Test bed for the development of genomic analysis technologies.**

**Well developed genetic analysis with defined mutant phenotypes.**

**Simpler eukaryotic genomes; many genes shared with human.**

**Amenable to experimental manipulation. Elucidation of gene biological and biochemical function.**

# Why study other genomes?

- \* Yeast

- \* *C. elegans*

- \* *Drosophila*

- \* *Fugu* (Puffer fish)

- \* Mouse

**Genome 10x less complex than  
human genome.**

**(smaller introns)**



# Why study other genomes?

- \* Yeast

- \* C. elegans

- \* Drosophila

- \* Fugu (Puffer fish)

- \* **Mouse**

**Model mammalian genome.**


**Sophisticated genetic map with defined phenotypes.**

**Comparative mapping allows prediction of human disease gene location for diseases modelled in mouse: by means of conserved gene order.**

**Transgenesis and homologous recombination permits investigation of gene function. Modelling of disease and therapeutic strategies.**

# Completion of genome sequence projects marks the start of genome-based biology

## How can genome information be exploited ?



# Genome Information and Resources Enable Genomic Approaches to Disease:

- **Candidate Gene Approaches**

- Association Studies Exploiting DNA Variation

- Functional Analysis


- DNA Microarrays- genome wide expression analysis of genes - Transcriptome
- Proteomics - defining proteins, their functions and interactions - Proteome
- Gene Inactivation - defining function through gene silencing
- Phenomics and Animal Models of Disease -Phenotype analysis – defining function through gene mutagenesis - Phenome

## **Two Variants:**

- \* The Candidate Gene Approach**
- \* The Positional Candidate Gene Approach**

# **The Candidate Gene Approach**


**From an understanding of the biology  
of the disease, identify protein with  
appropriate function**




**Correlate physical map location of  
gene encoding protein with any genetic  
location identified for disease by linkage**

**Mutation analysis of gene in patients to  
provide genetic evidence for involvement  
in the disease**

# The Positional Candidate Gene Approach



# The Power of an SNP Map of the Human Genome



**Detailed SNP Maps and  
Characterised Haplotypes Have  
Powerful Applications**

**Mapping of Disease  
Loci Causing  
Complex Polygenic  
Disease**


**Identification of  
Potential Drug  
Targets**

**Correlation of  
Haplotype to  
Response to Drugs**

**Rapid Marker  
Assisted Selection in  
Agricultural Animals**

**Detection of  
Susceptibility to Late  
Onset Polygenic  
Disease**

**Direct Detection  
of Mutations**





**Oligo tiling  
path across  
interval**

**Capture of sequences  
covering interval from  
DNA of affected individuals**

**Deep sequencing of  
entire interval to  
identify sequence**

**Changes**

**Exon**

Intron


Promoter

Intergenic

Non-coding RNA

36000000

57000000



# Relationship between Functional Approaches

Differential gene expression  
defining disease processes / state

**MICROARRAYS**

Differential protein expression  
and activity defining disease  
processes / state

**PROTEOMICS**


Transcriptional events  
and mRNA stability

Post-transcriptional  
events: Translational  
control  
Protein turnover  
Protein modification

Candidate genes  
for functional studies  
using gene silencing  
modelled in mouse etc

Genes leading to disease not  
defined by transcription profiling  
or proteome analysis

**MUTAGENESIS / PHENOTYPE SCREEN**



# Types of DNA Microarray

## DNA Arrays

### Arrays based on cloned DNA

### Oligonucleotide Arrays

### cDNA clones (From EST projects)

### Genomic DNA clones

**Synthesised *In Situ***  
**Affymetrix**  
**Illumina**  
**Agilent**  
**Nimblegen**

**Pre synthesised  
and arrayed**

# Why is transcription profiling so powerful?

- \*Defines genetic pathways and temporal transcription patterns in normal differentiation and disease processes.**
- \*Defines genes that show differential expression as potential targets for development of new drugs - Pharmacogenomics.**
- \*Transcriptional signatures of disease states can function to diagnose disease sub-types and indicate prognosis and most effective treatment eg leukaemias caused by translocations.**

**How is microarray data mined?** →

**Cluster analysis of  
differentially expressed  
genes to categorise  
expression profiles**



**Identification of  
genes in clusters**

**Verification of  
differential expression  
by real-time PCR/  
Northern analysis**

**Homology  
searches with  
novel genes**



**Identification of  
pathways altered  
in the disease state**


**Identification of motifs  
that may indicate  
biochemical function**

**Further functional  
studies**

**Diagnosics**

**Targets for  
drug development**

# The Challenge of Proteomics: **there are many more proteins than genes.**




## **How is the proteome being studied?:**

**\*2D Gels: Can resolve proteins that have undergone modifications. Phosphorylation, glycosylation etc.**


**\*Mass Spectroscopy: resolves oligopeptide patterns to identify proteins. Can be combined with 2D gels.**

**\*Protein Arrays: Analogous to DNA microarrays. Allows large scale protein / antibody interactions (useful in diagnostics). Allows protein and protein DNA interactions to be studied.**


**First Dimension**  
**Iso-electric focusing**



pH gradient gel



**Second Dimension**  
**SDS gel - separation on MW**



**Needs large amounts of material**

**Limited resolution**

**Low throughput**

**Proteins focus at their  
charge in the pH gradient**



**Digest into  
Oligopeptides**




**Mass Spec analysis  
to identify protein**




**Characterise protein**

**Excise  
protein**



# Applications of protein based arrays



- \* High throughput identification of proteins and complexes**
- \* High throughput isolation of interacting proteins compared to Yeast Two Hybrid system**
- \* Diagnostics based on antibody / antigen interactions e.g. ovarian cancer markers in serum**

# Linking Gene to Phenotype in Model Organisms

## \* Gene silencing through homologous recombination - genotype driven screen

- direct inactivation

- conditional inactivation by means of site-specific recombination using Cre recombinase

Labour intensive - cannot be applied on a genomic scale

Does not always cause a phenotype - redundant genetic pathways

## \* Gene silencing through the use of Interference RNA - RNAi

Highly specific distinguishing gene family members


Rapid and can be applied on a genomic scale e.g. plants, C. elegans, Drosophila

## \* ENU mutagenesis and phenotype driven analysis



Identifies genes by mutation saturation

Introduces different mutations per gene thus permitting analysis of functional domains



**Preparation of targeting construct containing part of gene**




**Transfection into Embryonal Stem Cells (ES)**




**Recombination with endogenous cellular gene**



**ES cell with inactivated gene**




**Introduction of ES cells into developing mouse blastocysts**



**Embryo develops into mouse with specific gene inactivated and associated phenotype**


**Needed when direct inactivation results in an embryonic lethal phenotype**

**Instead of directly silencing the gene in the ES cell, exons of the gene are flanked by Lox sites that direct site-specific recombination by the Cre recombinase. This is done in an ES cell transgenic for the Cre gene under the control of an inducible or tissue-specific promoter.**



- \*Developed and applied initially in plants, *C. elegans* and *Drosophila* and to mammalian cells in tissue culture**
- \*Highly gene specific capable of distinguishing related genes**
- \*Functions by subverting endogenous cellular pathways that utilise small double-stranded RNA molecules involved in gene regulation**

# Biogenesis of siRNA and miRNA




**N – ethyl – N – nitrosourea**

**ENU**

**An alkylating agent that transfers  
ethyl group to nucleobases**

**Targets spermatogonial stem cells  
and induces single base changes  
every 1 – 2 Mb at a rate of 1 per  
700 gametes**




**A>T base transversions; AT>GC transitions; also  
(less frequently) GC>AT transitions**

- \*ENU induces loss of function, gain of function, altered function mutations - wider range of phenotypes depending upon region of gene that is mutated**
- \*ENU mutagenesis is not biased - K.O. and RNAi *a priori* define the gene**
- \*ENU can alter more than one gene**
- \*Creates complex phenotypes**
- \*Phenotypes can be generated rapidly**



# **An Approach to the Phenome: Rapid Derivation of function from phenotype. cf Transgenic / K.O. mice**



## **Summary**

- 1. Genome projects have produced genome information resources that allow rapid identification of disease genes  
e.g. Maps, comparative maps, DNA sequence, SNPs**
- 2. Genome projects have produced resources for functional analysis e.g. microarray resources, clone banks**
- 3. Genome projects have forced the development of technologies to approach biology on a genome wide scale  
e.g. transcription profiling, proteomics and gene inactivation strategies**

# Summary

- 1. Genome projects have produced genome information resources that allow rapid identification of disease genes e.g. Maps, comparative maps, DNA sequence, SNPs**
- 2. Genome projects have produced resources for functional analysis e.g. microarray resources, clone banks**
- 3. Genome projects have forced the development of technologies to approach biology on a genome wide scale e.g. transcription profiling, proteomics, gene inactivation strategies and massively parallel sequencing approaches**

**Strachan and Reid Human Molecular Genetics 4<sup>th</sup> Edition (2011)**

**Chapters 12 and 16**